Axonics Modulation Technologies Inc.

56.64-0.8700-1.51%Vol 591.97K1Y Perf -11.13%
Jun 28th, 2022 16:00 DELAYED
BID50.58 ASK82.28
Open57.66 Previous Close57.51
Pre-Market- After-Market56.64
 - -  - -%
Target Price
70.00 
Analyst Rating
Strong Buy 1.17
Potential %
23.59 
Finscreener Ranking
★★★★+     55.11
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★+     53.93
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★     50.96
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
44.03 
Earnings Rating
Strong Buy
Market Cap2.67B 
Earnings Date
4th Aug 2022
Alpha0.04 Standard Deviation0.18
Beta0.51 

Today's Price Range

55.5458.97

52W Range

38.4179.81

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
15.67%
1 Month
9.90%
3 Months
-3.44%
6 Months
1.02%
1 Year
-11.13%
3 Years
40.37%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AXNX56.64-0.8700-1.51
AAPL137.44-4.2200-2.98
GOOG2 251.43-81.0200-3.47
MSFT256.48-8.4100-3.17
XOM91.502.47002.77
WFC40.18-0.0600-0.15
JNJ176.94-5.1800-2.84
FB196.640.99000.51
GE65.88-0.8300-1.24
JPM115.82-0.5600-0.48
Financial StrengthValueIndustryS&P 500US Markets
9.40
12.00
0.02
0.02
-11.80
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
66.20
-37.90
-32.30
-3 870.40
-41.32
RevenueValueIndustryS&P 500US Markets
194.34M
4.13
295.53
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.69-0.5027.54
Q04 2021-0.36-0.345.56
Q03 2021-0.46-0.3817.39
Q02 2021-0.51-0.59-15.69
Q01 2021-0.41-0.46-12.20
Q04 2020-0.32-0.299.38
Q03 2020-0.52-0.2453.85
Q02 2020-0.59-0.548.47
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.575.00Positive
9/2022 QR-0.59-5.36Negative
12/2022 FY-2.187.23Positive
12/2023 FY-1.507.98Positive
Next Report Date4th Aug 2022
Estimated EPS Next Report-0.57
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume591.97K
Shares Outstanding47.07K
Shares Float46.58M
Trades Count9.75K
Dollar Volume33.73M
Avg. Volume517.25K
Avg. Weekly Volume521.32K
Avg. Monthly Volume499.01K
Avg. Quarterly Volume531.42K

Axonics Modulation Technologies Inc. (NASDAQ: AXNX) stock closed at 57.51 per share at the end of the most recent trading day (a -1.81% change compared to the prior day closing price) with a volume of 758.21K shares and market capitalization of 2.67B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 302 people. Axonics Modulation Technologies Inc. CEO is Raymond Wayne Cohen.

The one-year performance of Axonics Modulation Technologies Inc. stock is -11.13%, while year-to-date (YTD) performance is 2.7%. AXNX stock has a five-year performance of %. Its 52-week range is between 38.41 and 79.81, which gives AXNX stock a 52-week price range ratio of 44.03%

Axonics Modulation Technologies Inc. currently has a PE ratio of -32.50, a price-to-book (PB) ratio of 5.95, a price-to-sale (PS) ratio of 13.93, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -16.97%, a ROC of -17.21% and a ROE of -20.70%. The company’s profit margin is -41.32%, its EBITDA margin is -32.30%, and its revenue ttm is $194.34 Million , which makes it $4.13 revenue per share.

Of the last four earnings reports from Axonics Modulation Technologies Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.57 for the next earnings report. Axonics Modulation Technologies Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Axonics Modulation Technologies Inc. is Strong Buy (1.17), with a target price of $70, which is +23.59% compared to the current price. The earnings rating for Axonics Modulation Technologies Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Axonics Modulation Technologies Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Axonics Modulation Technologies Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 9.20, ATR14 : 3.65, CCI20 : 104.88, Chaikin Money Flow : 0.07, MACD : 0.73, Money Flow Index : 69.89, ROC : -0.78, RSI : 59.30, STOCH (14,3) : 85.14, STOCH RSI : 0.88, UO : 62.17, Williams %R : -14.86), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Axonics Modulation Technologies Inc. in the last 12-months were: Alfred J. Ford (Option Excercise at a value of $0), Alfred J. Ford (Sold 9 267 shares of value $447 152 ), Danny L. Dearen (Option Excercise at a value of $986 241), Danny L. Dearen (Sold 88 594 shares of value $4 612 839 ), Jane E. Kiernan (Sold 5 250 shares of value $317 607 ), John Woock (Option Excercise at a value of $79 100), John Woock (Sold 46 251 shares of value $3 027 691 ), Karen Noblett (Option Excercise at a value of $0), Karen Noblett (Sold 20 213 shares of value $1 096 780 ), Raymond Wayne Cohen (Option Excercise at a value of $0), Raymond Wayne Cohen (Sold 185 115 shares of value $11 190 869 ), Rinda Sama (Option Excercise at a value of $0), Rinda Sama (Sold 11 882 shares of value $573 331 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (83.33 %)
6 (85.71 %)
6 (85.71 %)
Moderate Buy
1 (16.67 %)
1 (14.29 %)
1 (14.29 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.17
Strong Buy
1.14
Strong Buy
1.14

Axonics Modulation Technologies Inc.

Axonics Modulation Technologies Inc is a United stated based medical technology company. It focuses on the design, development, and commercialization of innovative and minimally invasive sacral neuromodulation (SNM) solutions. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention. The company has designed and developed the r-SNM System, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder and fecal incontinence.

CEO: Raymond Wayne Cohen

Telephone: +1 949 396-6322

Address: 26 Technology Drive, Irvine 92618, CA, US

Number of employees: 302

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

70%30%

Bearish Bullish

62%38%

News

Stocktwits